Christine M. Eischen

Thomas Jefferson University — United States

Medicine · Health Sciences

49h-index8.8kcitations244works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(65), Histone Deacetylase Inhibitors Research(36), Protein Degradation and Inhibitors(30), Click Chemistry and Applications(26), DNA Repair Mechanisms(25)

Publications244 total

Supplementary Data from Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer
2025Open Access
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells
Blood Advances·2025· 1 citedOpen Access
Distinct Cell-Intrinsic and Extrinsic Consequences of TLR2 Activation Drive Pleiotropic Effects in AML Affecting Overall Survival
Blood·2024
<scp>DNA</scp> fork remodeling proteins, Zranb3 and Smarcal1, are uniquely essential for aging hematopoiesis
Aging Cell·2024· 3 citedOpen Access
Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma
Cancers·2024· 1 citedOpen Access
Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Table S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Supplementary Methods from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S7 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S4 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S2 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Data from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S8 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Table S3 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Table S1 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
Figure S5 from 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
2024Open Access
page 1 of 13Next →

Frequent Co-authors

Ramkrishna Mitra(10), Clare M. Adams(10), John L. Cleveland(7), Zhongming Zhao(7), Martine F. Roussel(5), Paul J. Leibson(5), Alyssa Bouska(5), Lance R. Thomas(4), Shelly L. Lorey(4), William P. Tansey(4), Charles J. Sherr(3), Gregory C. Howard(3), Stephen W. Fesik(3), Laura Y. McGirt(3), Stephen N. Jones(3), Scott W. Hiebert(3), Maria P. Arrate(3), Brian C. Grieb(2), Audra F. Bryan(2), Edward T. Olejniczak(2)